Navigation Links
New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
Date:9/19/2007

en infrequent reports of severe and occasionally incapacitating bone, joint and/or muscle pain. Rare occurrences of osteonecrosis, primarily of the jaw (ONJ), have been reported in patients receiving bisphosphonates. Most ONJ cases have occurred in cancer patients undergoing dental procedures. In the majority of cases reported, patients had received intravenous bisphosphonate therapy.

In clinical trials of up to 3-years duration, the overall incidence of adverse events with Actonel 5 mg daily was comparable to placebo. The most commonly reported adverse events regardless of causality were infection (primarily upper respiratory, placebo 29.7% vs Actonel 5 mg 29.9%), back pain (23.6% vs 26.1%), and arthralgia (21.1% vs 23.7%).

In a clinical trial comparing Actonel 35 mg Once-a-Week and Actonel 5 mg daily for 1 year, the overall safety and tolerability profiles of the two dosing regimens were similar. The most commonly reported adverse events regardless of causality were infection (Actonel 35 mg 20.6% vs Actonel 5 mg 19.0%), arthralgia (14.2% vs 11.5%) and constipation (12.2% vs 12.5%).

In a clinical trial comparing Actonel 75 mg two consecutive days/month and Actonel 5 mg daily for 1 year, the overall safety and tolerability profiles of the two dosing regimens were similar. The most commonly reported adverse events regardless of causality were arthralgia (Actonel 75 mg 10.4% vs Actonel 5 mg 9.5%), dyspepsia (9.1% vs 7.3%), and back pain (8.8% vs 10.8%).

Please see full prescribing information for Actonel(R) (risedronate sodium tablets) for additional safety information. For a copy of the full prescribing information for Actonel visit the Actonel Web site at http://www.actonel.com.

About The Alliance for Better Bone Health

The Alliance for Better Bone Health was formed in May 1997 to promote bone health and disease awareness through numerous activities to support physicians and patie
'/>"/>

SOURCE The Alliance for Better Bone Health
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... N.J. , May 4, 2015  Oncobiologics, ... commercializing monoclonal antibody (mAb) biosimilars, has completed the ... at its headquarters in Cranbury, New ... Cranbury facility is designed to utilize ... manufacturing at commercial scale.  Through the use of ...
(Date:5/4/2015)... 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... HealthCare (Bayer) to develop and commercialize ISIS-FXI Rx ... the agreement, Isis is eligible to receive up to ... million up-front payment and a $55 million payment upon ... in patients with compromised kidney function. Isis is also ...
(Date:5/4/2015)... 2015  Geneia, a company of experienced healthcare ... improve healthcare efficiencies, today announced a first-of-its-kind partnership ... (BNRC) use Geneia,s advanced analytics solution coupled with ... and lower the cost of patient care. ... and utilization data from multiple sources to create ...
Breaking Medicine Technology:Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 2Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 3
... Privigen®, the first and only ... proline, is effective and well tolerated in patients ... data presented today at the XIVth Meeting of ... that Privigen offers significant protection against ...
... CHAPEL HILL, N.C., Oct. 6 Pharmaceutical and biotech ... they ensure strong partnerships between R&D and marketing, balancing ... product development. It requires companies to break down the ... instead leverage the strengths of both talented medical researchers ...
Cached Medicine Technology:Privigen® Demonstrates Efficacy and Tolerability Among Patients With Various Immunodeficiencies, Data Show 2Privigen® Demonstrates Efficacy and Tolerability Among Patients With Various Immunodeficiencies, Data Show 3Creating Partnerships Across R&D and Marketing to Ensure a Successful Global Launch 2
(Date:5/4/2015)... NY (PRWEB) May 04, 2015 Sheltering ... Learning Center from Hale House. The Mother Hale Learning ... high-quality, affordable Early Childhood Education. Sheltering Arms will begin ... continue to be served by the center. , Opened ... children ages six weeks to five years, many of ...
(Date:5/4/2015)... May 04, 2015 New West Medicare ... to Care, LLC to manage outpatient advanced imaging services ... West Medicare ensure its members are provided the right ... , Working closely with New West Medicare’s physicians and ... safe use of advanced imaging and provide an objective ...
(Date:5/4/2015)... 04, 2015 Elisabeth Rosenthal’s article* ... stir and showed the healthcare fraternity as well ... procedure, the downside of balance billing. In definition, ... provider billing a patient for the difference between ... and what the provider chooses to charge. Rosenthal’s ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 In ... US Preventive Services Task Force (USPSTF), Strategic Radiology® ... American Congress of Obstetricians and Gynecologists (ACOG), the ... the Cure, American Cancer Society (ACS), American College ... (SBI) to unanimously recommend regular screening mammography for ...
(Date:5/4/2015)... 2015 World T.E.A.M. Sports’ best-attended ... in the last decade arrived in this historic Civil ... two days from the Pentagon in Arlington, Virginia. The ... disabled and able-bodied participants work together to successfully complete ... honors the commitment and sacrifices by military veterans in ...
Breaking Medicine News(10 mins):Health News:Sheltering Arms Acquires the Mother Hale Learning Center 2Health News:New West Medicare Partners with Care to Care, LLC to Manage Advanced Imaging Services 2Health News:Out of Network Balance Billing Without Being Viewed as Fraud 2Health News:Out of Network Balance Billing Without Being Viewed as Fraud 3Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 2Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 3Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 4Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 5Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 2Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 3Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 4
... anthrax attack killed a photo editor has been deemed safe, ... officials. ,Bob Stevens, a photo editor for American ... anthrax in an envelope mailed to the building, which housed ... part of a wave of anthrax attacks and hoaxes that ...
... authorities on Thursday expressed confidence in their efforts to reduce ... of bird flu, after two separate incidents at poultry farms ... not over [for bird flu], but we have sufficient monitoring ... any sporadic cases that might occur," Muhammad Afzal, a spokesman ...
... latest study sleep deprivation could affect the functioning of brain ... from Princeton University. They conducted this study on rats. ... group whose sleep was deprived for 72 hours and the ... of sleep in the first group affected a region in ...
... Johns Hopkins Kimmel Cancer Center scientists have found a ... cells in their primitive state//. Unlocking the switches' code ... cells for transplant into patients with cancer and other ... control switches not at the gene level, but farther ...
... shed on proteorhodopsin, the light-sensitive protein found in many ... Energy’s Lawrence// Berkeley National Laboratory (Berkeley Lab) and the ... the ability to respire oxygen is impaired, bacterium equipped ... out vital life processes. ,“Our research ...
... conducted in 100 pregnant women with anti-Ro and anti-La ... could be treated in early stages//. ,There ... mothers carry particular antibodies associated with rheumatic diseases, according ... researchers at the Society for Maternal-Fetal Medicine Conference February ...
Cached Medicine News:Health News:Pakistan: Authorities Plays Down Bird Flu Risk 2Health News:Master Switches Found for Adult Blood Stem Cells 2Health News:Shedding New Light on Proteorhodopsin 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: